Home > News & Media > News
Communication starts here.
2016.11
TWi announces the disposal of its equity investment at Visum
2016.11
TWi Settles Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Androgel 1.62%
2016.11
Par Pharmaceutical Drops Appeal And Agrees To Pay TWi Pharmaceuticals The Full Amount Of Damages Awarded By The District Court
2016.10
Par Pharmaceutical, Inc filed its notice of appeal for the distribution of injunction bonds in generic Megace ES patent suit
2016.09
TWi Pharmaceuticals Awarded US$12.7 Million In Generic MEGACE ES® Patent Suit
2016.09
TWi Confirms Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Androgel 1.62%
2015.09
TWi Pharmaceuticals Issues GDR and raised NT$ 2.83 Billion
2015.09
TWi Pharmaceuticals President & CEO Ms. Tina Guilder will resign from her current roles and Chairman Dr. Chih-Ming Chen will become interim President & CEO
2015.08
TWi Pharmaceuticals Announces 2Q 2015 Financial Results and EPS for 2Q of NT$0.69
2015.08
TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia

 

Pages:1 - 2 - 3 - 4 - 5 - 6 - 7 - 8« Pre · Next »